Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical.
AMA J Ethics. 2018;20(12):E1133-1138. doi:
10.1001/amajethics.2018.1133.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Medical students’ moral distress about end-of-life cases can be reduced through ethics consultation and ethics rounds, narrative reflection, and mentoring.
AMA J Ethics. 2017;19(6):585-594. doi:
10.1001/journalofethics.2017.19.6.stas1-1706.
The convening power of clinical ethics committees stems from their reputation for fairness and procedural legitimacy in addressing and resolving ethically complex cases.
AMA J Ethics. 2016;18(5):540-545. doi:
10.1001/journalofethics.2016.18.5.msoc2-1605.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Regularly scheduled dialysis is not standard of care for most undocumented immigrants in the United States, so preventative care, and advocacy for it, is needed.
AMA J Ethics. 2019;21(1):E86-92. doi:
10.1001/amajethics.2019.86.